Payment overview · 2025
General Payments
$1,991.24
99 reported records · 27 companies
Healthcare provider profile · identity verified
Ian Boykin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT PIERCE, FL · NPI 1891772596
Verified facts
What the public records show
CMS Open Payments records show Ian Boykin, MD received $1,991.24 in general payments during 2025 across 99 reported records.
PFIZER INC. accounted for 12.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance, Kerendia, Mounjaro, Otezla, Ozempic, Rybelsus, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 619 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Aptiom by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $241.99 | 12.2% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.51 | 9.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $182.91 | 9.2% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.14 | 7.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $126.55 | 6.4% | 7 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $125.00 | 6.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $110.40 | 5.5% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $93.01 | 4.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.68 | 4.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.66 | 4.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $79.37 | 4.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $63.17 | 3.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.61 | 2.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.14 | 2.4% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $44.19 | 2.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.15 | 2.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.89 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.84 | 1.8% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $33.18 | 1.7% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $27.24 | 1.4% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $26.00 | 1.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.96 | 1.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.79 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.36 | 1.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.69 | 0.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.05 | 0.8% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $14.76 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,991.24 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $198.79 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $150.14 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $128.94 | 6 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $95.87 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $93.01 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $91.60 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $91.31 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $85.68 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.68 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $83.06 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.66 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.66 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $79.37 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $72.62 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $70.93 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $69.85 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $66.56 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $63.17 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.22 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $44.19 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $43.20 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.84 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $27.24 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $6.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 619 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 32 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 75 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 185 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
94 | 34 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
185 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
619 | 116 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1663 | 516 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1369 | 409 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1050 | 372 |
| Amlodipine Besylate | Amlodipine Besylate | 1025 | 324 |
| Losartan Potassium | Losartan Potassium | 983 | 300 |
| Lisinopril | Lisinopril | 803 | 256 |
| Alprazolam | Alprazolam | 720 | 183 |
| Metformin Hcl | Metformin Hcl | 693 | 215 |
| Omeprazole | Omeprazole | 624 | 201 |
| Eliquis | Apixaban | 619 | 116 |
| Furosemide | Furosemide | 615 | 174 |
| Metoprolol Tartrate | Metoprolol Tartrate | 607 | 172 |
| Simvastatin | Simvastatin | 582 | 184 |
| Tamsulosin Hcl | Tamsulosin Hcl | 558 | 166 |
| Gabapentin | Gabapentin | 536 | 167 |
| Metoprolol Succinate | Metoprolol Succinate | 504 | 154 |
| Pantoprazole Sodium | Pantoprazole Sodium | 479 | 166 |
| Hydrochlorothiazide | Hydrochlorothiazide | 452 | 146 |
| Clopidogrel | Clopidogrel Bisulfate | 435 | 132 |
| Potassium Chloride | Potassium Chloride | 402 | 107 |
| Sertraline Hcl | Sertraline Hcl | 385 | 117 |
| Ezetimibe | Ezetimibe | 348 | 119 |
| Zolpidem Tartrate | Zolpidem Tartrate | 337 | 92 |
| Allopurinol | Allopurinol | 322 | 99 |
| Trazodone Hcl | Trazodone Hcl | 321 | 110 |
| Tramadol Hcl | Tramadol Hcl | 311 | 132 |
| Pravastatin Sodium | Pravastatin Sodium | 308 | 96 |
| Famotidine | Famotidine | 292 | 103 |
| Fenofibrate | Fenofibrate | 277 | 86 |
| Escitalopram Oxalate | Escitalopram Oxalate | 271 | 91 |
| Atenolol | Atenolol | 260 | 73 |
| Alendronate Sodium | Alendronate Sodium | 258 | 83 |
| Carvedilol | Carvedilol | 234 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 222 | 63 |
| Montelukast Sodium | Montelukast Sodium | 216 | 70 |
| Temazepam | Temazepam | 200 | 41 |
| Finasteride | Finasteride | 197 | 61 |
| Donepezil Hcl | Donepezil Hcl | 190 | 55 |
| Lorazepam | Lorazepam | 188 | 54 |
| Ozempic | Semaglutide | 185 | 50 |
| Meloxicam | Meloxicam | 175 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 68 |
| Mirtazapine | Mirtazapine | 165 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 160 | 57 |
| Memantine Hcl | Memantine Hcl | 151 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 142 | 47 |
| Clonazepam | Clonazepam | 139 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 39 |
| Valsartan | Valsartan | 127 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 52 |
| Glipizide | Glipizide | 115 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 113 | 27 |
| Buspirone Hcl | Buspirone Hcl | 111 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 33 |
| Celecoxib | Celecoxib | 102 | 38 |
| Lactulose | Lactulose | 102 | 27 |
| Bupropion Xl | Bupropion Hcl | 100 | 31 |
| Diazepam | Diazepam | 100 | 33 |
| Ibandronate Sodium | Ibandronate Sodium | 98 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 34 |
| Spironolactone | Spironolactone | 96 | 33 |
| Synthroid | Levothyroxine Sodium | 94 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 90 | 74 |
| Pregabalin | Pregabalin | 90 | 31 |
| Nifedipine Er | Nifedipine | 88 | 27 |
| Lovastatin | Lovastatin | 86 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 84 | 24 |
| Januvia | Sitagliptin Phosphate | 83 | 28 |
| Latanoprost | Latanoprost | 83 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 30 |
| Humalog Kwikpen U-100 | Insulin Lispro | 81 | 17 |
| Warfarin Sodium | Warfarin Sodium | 81 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 79 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 79 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 79 | 54 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | 22 |
| Clonidine Hcl | Clonidine Hcl | 78 | 37 |
| Fenofibrate | Fenofibrate,micronized | 77 | 22 |
| Glimepiride | Glimepiride | 77 | 30 |
| Jardiance | Empagliflozin | 75 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 73 | 29 |
| Prednisone | Prednisone | 72 | 37 |
| Testosterone Cypionate | Testosterone Cypionate | 70 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 17 |
| Trulicity | Dulaglutide | 66 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 24 |
| Metformin Hcl Er | Metformin Hcl | 65 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 18 |
| Xarelto | Rivaroxaban | 64 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 63 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 19 |
| Clonidine | Clonidine | 61 | 14 |
| Bumetanide | Bumetanide | 59 | 16 |
| Nystatin | Nystatin | 59 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 58 | 31 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 18 |
| Anastrozole | Anastrozole | 56 | 14 |
| Divalproex Sodium | Divalproex Sodium | 56 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 18 |
| Valacyclovir | Valacyclovir Hcl | 55 | 23 |
| Methocarbamol | Methocarbamol | 54 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 17 |
| Sucralfate | Sucralfate | 54 | 15 |
| Baclofen | Baclofen | 53 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 35 |
| Ibuprofen | Ibuprofen | 52 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 30 |
| Ramipril | Ramipril | 51 | 18 |
| Mounjaro | Tirzepatide | 50 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 14 |
| Amoxicillin | Amoxicillin | 48 | 32 |
| Levetiracetam | Levetiracetam | 48 | 17 |
| Kerendia | Finerenone | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 31 |
| Multaq | Dronedarone Hcl | 44 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | 16 |
| Timolol Maleate | Timolol Maleate | 44 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 40 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 11 |
| Repatha Sureclick | Evolocumab | 40 | 13 |
| Cephalexin | Cephalexin | 39 | 31 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 15 |
| Folic Acid | Folic Acid | 38 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 11 |
| Methylprednisolone | Methylprednisolone | 36 | 27 |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Linzess | Linaclotide | 35 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 14 |
| Lubiprostone | Lubiprostone | 34 | suppressed |
| Metolazone | Metolazone | 34 | suppressed |
| Cefdinir | Cefdinir | 33 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 15 |
| Novolog Flexpen | Insulin Aspart | 33 | 13 |
| Xifaxan | Rifaximin | 33 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | 15 |
| Meclizine Hcl | Meclizine Hcl | 32 | 15 |
| Metronidazole | Metronidazole | 32 | 15 |
| Topiramate | Topiramate | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Estradiol | Estradiol | 31 | 11 |
| Midodrine Hcl | Midodrine Hcl | 31 | 14 |
| Telmisartan | Telmisartan | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | 11 |
| Lacosamide | Lacosamide | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | 14 |
| Ketoconazole | Ketoconazole | 28 | 14 |
| Primidone | Primidone | 28 | suppressed |
| Otezla | Apremilast | 27 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 26 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | 12 |
| Daptomycin | Daptomycin | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | 13 |
| Naproxen | Naproxen | 25 | 11 |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 24 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 24 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Rytary | Carbidopa/Levodopa | 23 | suppressed |
| Ampicillin Sodium | Ampicillin Sodium | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Glucagon Emergency Kit | Glucagon | 20 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Victoza 2-Pak | Liraglutide | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,991.24 · 99 records | PFIZER INC. | AIRSUPRA, AMPLATZER AMULET, Arikayce, BREZTRI, BRUKINSA, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, ETERNA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, General - Pain Management, INGREZZA, INJECTAFER, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, Natroba, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Spinosad, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error